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Sir, 27 
The CLSI recently published new interpretive criteria for the anti-pseudomonal 28 
penicillins and carbapenems for susceptibility testing of Pseudomonas aeruginosa [1]. The 29 
susceptible breakpoints for piperacillin and piperacillin-tazobactam were lowered from ≥18 30 
mm (piperacillin component, MIC ≤64 g/ml) to ≥21 mm (MIC ≤16 g/ml); that for 31 
ticarcillin-clavulanate and imipenem were lowered from ≥15 mm (ticarcillin component, ≤64 32 
g/ml) to ≥24 mm (≤16 g/ml) and from ≥16 mm (≤4 g/ml) to ≥19 mm (≤2 g/ml), 33 
respectively [1,2]. Here, the computerized database from January 2009 to December 2011 in 34 
a clinical microbiology laboratory for P. aeruginosa was used to assess how implementation 35 
of the new interpretive criteria would have affected the susceptibility categorization. In the 36 
laboratory, the CLSI’s disk diffusion method was used routinely for susceptibility testing of 37 
bacteria [3].  38 
 The results for 11540 P. aeruginosa isolates were analysed. Inhibition zone 39 
distributions showed that the new susceptibility breakpoints for ticarcillin-clavulanate were 40 
close to and larger than the modal value for the bacterial collection. On the other hand, the 41 
new susceptibility breakpoints for piperacillin, piperacillin-tazobactam and imipenem 42 
remained much smaller than the modal inhibition zone values. The mean ( standard 43 
deviation) and mode inhibition zone diameters were as follows: piperacillin, 25.9 ( 5.6) and 44 
28 mm; piperacillin-tazobactam, 26.4 ( 6.6) and 30 mm; ticarcillin-clavulanate, 20.8 ( 5.4) 45 
and 22 mm; and imipenem, 25.0 ( 5.5) and 25 mm. Therefore, implementation of the new 46 
interpretive criteria (Table 1) would drastically reduce the susceptibility rate for ticarcillin-47 
clavulanate (-49.4%). The changes in the susceptibility rates for the other three agents were 48 
modest: piperacillin (-3.5%), piperacilin-tazobactam (-2.8%) and imipenem (-1.8%). To 49 
assess the effect of the new interpretive criteria on isolates from different sources, we further 50 
analysed the results according four specimen groups (blood, urine, respiratory and other 51 
 3
specimens). At the old interpretive criteria, 83.2-84.1% of the isolates were susceptible to 52 
ticarcillin-clavulanate. When the results were interpreted by the new interpretive criteria, the 53 
ticarcillin-clavulanate susceptibility rates declined to 26.5-38.0%. The reduction in ticarcillin-54 
clavulanate susceptibility rate was most pronounced for isolates from blood specimens (-55 
56.6%), followed by urine (-55.9%), other specimens (-51.2%) and urine (-45.2%).  56 
 We submit that the new CLSI breakpoints for ticarcillin-clavulanate are debatable for 57 
several reasons. Firstly, for ticarcillin-clavulanate, the same disc content and virtually the 58 
same methodology was recommended by the CLSI and European Committee on 59 
Antimicrobial Susceptibility Testing (EUCAST) for testing P. aeruginosa [1,4]. According to 60 
the EUCAST, the inhibition zone diameter deems to be equivalent to the interpretive 61 
breakpoint ≤16 g/ml (ticarcillin component) is ≥17 mm. At the breakpoint of ≥17 mm, 62 
78.3% of the P. aeruginosa in this study would be classified as ticarcillin-clavulanate 63 
susceptible. Since the disc contents recommended for testing piperacillin and piperacillin-64 
tazobactam by the CLSI and EUCAST are different, our inhibition zone distributions could 65 
not be interpreted by the EUCAST breakpoints. Secondly, it has been argued that 66 
susceptibility breakpoints should not be set to cut into the wild type inhibition zone (or MIC) 67 
distribution. Otherwise, large number of isolates would be interpreted as resistant and many 68 
isolates would shift between different interpretation categories when tested by different 69 
laboratories or upon retesting by the same laboratory. In our locality, ticarcillin-clavulanate 70 
has been widely used for treatment of various types of P. aeruginosa infections and clinical 71 
failures are uncommon [5]. Implementation of the new CLSI interpretive criteria would mean 72 
that very few P. aeruginosa isolates would then remain ticarcillin-clavulanate susceptible and 73 
clinicians would be led to prescribe other more expensive anti-pseudomonal antimicrobial 74 
agents.   75 
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Table 1. Comparison of the susceptibility rates for 11540 P. aeruginosa to selected antimicrobial agents using the M100-S21 and M100-S22 87 
CLSI interpretive criteria 88 
Organism and agent % Susceptible % Intermediate  % Resistant Difference 
in % susceptibleb 
 CLSI-2011a CLSI-2012a CLSI-2011 CLSI-2012  CLSI-2011 CLSI-2012  
Piperacillin 92.7 89.2 - 5.7  7.3 5.1 -3.5 
Piperacillin-tazobactam 93.9 91.1 - 4.4  6.1 4.4 -2.8 
Ticarcillin-clavulanate 83.5 34.1 - 19.8  16.5 46.1 -49.4 
Imipenem 91.3 89.5 1.1 8.7  7.6 1.7 -1.8 
aAccording to the interpretive criteria published by the CLSI in January 2011 (M100-S21) [2] and January 2012 (M11-S22) for P. aeruginosa. 89 
The 2011/2012 CLSI breakpoints, i.e. inhibition zone diameters (equivalent MIC), were as follows: piperacillin (with or without tazobactam), 90 
susceptible ≥18 mm (≤64 g/ml)/≥21 mm (≤16 g/ml); intermediate, none/15-20 mm (32-64 g/ml); and resistant, ≤17 mm (≥128 g/ml)/≤14 91 
mm (≥128 g/ml); ticarcillin (with or without clavulanate), susceptible, ≥15 mm (≤64 g/ml)/≥24 mm (≤16 g/ml); intermediate, none/16-23 92 
mm (32-64 g/ml); and resistant, ≤14 mm (≥128 g/ml)/≤15 mm (≥128 g/ml); and imipenem, susceptible, ≥16 mm (4 g/ml)/≥19 mm (≤2 93 
g/ml); intermediate, 14-15 mm (8 g/ml)/16-18 mm (4 g/ml); resistant, ≤13 mm (≥16 g/ml)/≤15 mm (≥8 g/ml).   94 
bP value <0.001 for all comparisons (CLSI 2011 versus 2012).      95 
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